ABBV-903 / AbbVie - LARVOL DELTA

A Study to Assess the Relative Bioavailability of Three Immediate-Release Tablet Formulations of ABBV-903 in Healthy Adult Volunteers (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: AbbVie | N=30 ➔ 0 | Trial completion date: Dec 2023 ➔ Jan 2025 | Initiation date: Oct 2023 ➔ Dec 2024 | Not yet recruiting ➔ Withdrawn | Trial primary completion date: Dec 2023 ➔ Jan 2025

Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date • Trial withdrawal

A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese Participants (clinicaltrials.gov) - P1 | N=24 | Terminated | Sponsor: AbbVie | N=42 ➔ 24 | Recruiting ➔ Terminated; Strategic considerations

Enrollment change • Trial termination

A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult Healthy Volunteers (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: AbbVie | Active, not recruiting ➔ Completed

Trial completion

A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults (clinicaltrials.gov) - P1 | N=104 | Completed | Sponsor: AbbVie | Active, not recruiting ➔ Completed

Adverse events • Trial completion

A Study to Assess the Mass Balance of [14C] ABBV-903 in Healthy Male Participants Following Single Oral Dose Administration (clinicaltrials.gov) - P1 | N=7 | Completed | Sponsor: AbbVie | Active, not recruiting ➔ Completed

Trial completion

A Study to Assess the Relative Bioavailability of Three Immediate-Release Tablet Formulations of ABBV-903 in Healthy Adult Volunteers (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: AbbVie

New P1 trial

A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult Healthy Volunteers (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults (clinicaltrials.gov) - P1 | N=104 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting

Adverse events • Enrollment closed

A Study to Assess the Mass Balance of [14C] ABBV-903 in Healthy Male Participants Following Single Oral Dose Administration (clinicaltrials.gov) - P1 | N=7 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese Participants (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Assess the Mass Balance of [14C] ABBV-903 in Healthy Male Participants Following Single Oral Dose Administration (clinicaltrials.gov) - P1 | N=7 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese Participants (clinicaltrials.gov) - P1 | N=42 | Not yet recruiting | Sponsor: AbbVie

New P1 trial

A Study to Assess the Mass Balance of [14C] ABBV-903 in Healthy Male Participants Following Single Oral Dose Administration (clinicaltrials.gov) - P1 | N=7 | Not yet recruiting | Sponsor: AbbVie

New P1 trial

A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: AbbVie | Active, not recruiting ➔ Completed

Trial completion

A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult Healthy Volunteers (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult Healthy Volunteers (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: AbbVie

New P1 trial

A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults (clinicaltrials.gov) - P1 | N=84 | Recruiting | Sponsor: AbbVie | Trial completion date: May 2023 ➔ Sep 2023 | Trial primary completion date: May 2023 ➔ Sep 2023

Adverse events • Trial completion date • Trial primary completion date

A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: AbbVie

New P1 trial